Effectiveness of treatments for advanced non–small-cell lung cancer with exon 20 insertion epidermal growth factor receptor mutations
Background Two main categories of epidermal growth factor receptor (EGFR) mutations in
non–small-cell lung cancer (NSCLC) patients are deletions in exon 19 and L858R in exon …
non–small-cell lung cancer (NSCLC) patients are deletions in exon 19 and L858R in exon …
Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR …
A Sutani, Y Nagai, K Udagawa, Y Uchida… - British journal of …, 2006 - nature.com
This study was prospectively designed to evaluate a phase II study of gefitinib for non-small-
cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations …
cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations …
'Classical'but not 'other'mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
Abstract 'Classical'mutations in the EGFR tyrosine kinase domain (exons 18, 19 and 21)
have been associated with sensitivity to tyrosine kinase inhibitors (TKIs) in patients with …
have been associated with sensitivity to tyrosine kinase inhibitors (TKIs) in patients with …
Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non–small-cell lung cancer
T Takano, Y Ohe, H Sakamoto, K Tsuta… - Journal of clinical …, 2005 - ascopubs.org
Purpose To evaluate epidermal growth factor receptor (EGFR) mutations and copy number
as predictors of clinical outcome in patients with non–small-cell lung cancer (NSCLC) …
as predictors of clinical outcome in patients with non–small-cell lung cancer (NSCLC) …
Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC
S Dufort, MJ Richard, S Lantuejoul… - Journal of Experimental & …, 2011 - Springer
Abstract Background Epidermal Growth Factor Receptor (EGFR) mutations, especially in-
frame deletions in exon 19 (ΔLRE) and a point mutation in exon 21 (L858R) predict gefitinib …
frame deletions in exon 19 (ΔLRE) and a point mutation in exon 21 (L858R) predict gefitinib …
Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status
T Onitsuka, H Uramoto, N Nose, M Takenoyama… - Lung Cancer, 2010 - Elsevier
BACKGROUND: Some types of somatic mutation of the epidermal growth factor receptor
(EGFR) gene in non-small cell lung cancer (NSCLC) are associated with a significant …
(EGFR) gene in non-small cell lung cancer (NSCLC) are associated with a significant …
EGFR Mutation Status in Japanese Lung Cancer Patients: Genotyping Analysis Using LightCycler
H Sasaki, K Endo, A Konishi, M Takada… - Clinical cancer …, 2005 - AACR
Purpose: Recently, somatic mutations of the epidermal growth factor receptor (EGFR) gene
were found in∼ 25% of Japanese lung cancer patients. These EGFR mutations are reported …
were found in∼ 25% of Japanese lung cancer patients. These EGFR mutations are reported …
[HTML][HTML] The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer
XT Zhang, LY Li, XL Mu, QC Cui, XY Chang, W Song… - Annals of oncology, 2005 - Elsevier
Background: The aim of the study was to evaluate the efficacy of gefitinib and the epidermal
growth factor receptor (EGFR) mutation to gefitinib response in a series of Chinese patients …
growth factor receptor (EGFR) mutation to gefitinib response in a series of Chinese patients …
Biological and clinical implications of EGFR mutations in lung cancer
T Mitsudomi, T Kosaka, Y Yatabe - International journal of clinical …, 2006 - Springer
Background Patients with non-small-cell lung cancer sometimes show a dramatic clinical
response to gefitinib or erlotinib, small-molecule tyrosine kinase inhibitors (TKI) specific for …
response to gefitinib or erlotinib, small-molecule tyrosine kinase inhibitors (TKI) specific for …
Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with EGFR Mutations
S Morita, I Okamoto, K Kobayashi, K Yamazaki… - Clinical Cancer …, 2009 - AACR
Purpose: Somatic mutations of the epidermal growth factor receptor (EGFR) gene are
associated with an increased response to gefitinib in patients with non–small cell lung …
associated with an increased response to gefitinib in patients with non–small cell lung …